Beijing Doimmun Biotech

Beijing Doimmun Biotech is a clinical-stage biopharmaceutical company based in Beijing, China, dedicated to the development of innovative multi-specific antibody therapies for cancer. The company utilizes its proprietary protein engineering platforms to design biologics that simultaneously target immune checkpoints and costimulatory pathways, aiming to overcome the limitations of current monotherapies. Its lead candidate, DI-001, is a bispecific antibody targeting PD-L1 and 4-1BB, currently in Phase 1 clinical trials for advanced solid tumors. Doimmun's pipeline also includes several undisclosed programs focusing on T-cell engagers and other multi-specific modalities. The company is backed by prominent investors such as Northern Light Venture Capital and ZhenFund. By integrating deep immunological insights with advanced engineering, Doimmun Biotech strives to provide next-generation treatments for patients with refractory malignancies.